CTXR Stock Analysis: Buy, Sell, or Hold?
CTXR - Citius Pharmaceuticals Inc. Common
$0.60
0.01 (2.06%)
▲
5d:
+3.27%
30d:
-5.88%
90d:
+9.81%
BUY
MODERATE Confidence
Analysis Updated: Sep 18, 2026 12:00 AM ET
Earnings: Aug 18, 2026
0d
Get Alerted When CTXR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CTXR shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: CTXR shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CTXR is currently trading at $0.60, which is considered fair relative to its 30-day fair value range of $0.55 to $0.67. From a valuation perspective, the stock is trading at a discount (Forward PE: -0.4) compared to its historical average (0.3). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CTXR is in a uptrend. The price is approaching resistance at $0.62. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CTXR scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $4.00 (+566.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CTXR is in a uptrend. The price is approaching resistance at $0.62. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CTXR scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $4.00 (+566.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.55 -
$0.67
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
88.1%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (63/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 566.7% below Wall St target ($4.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- BULLISH: Bottoming setup score 63/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$0.55 -
$0.67
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$0.56
Resistance Level
$0.62
Current Trend
Uptrend
Technical data as of
Sep 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.42
Wall Street Target
$4.00
(+566.7%)
PE vs Historical
-0.4 vs 0.3
CHEAP
Share & Embed Analysis
Last updated: September 18, 2026 6:21 PM ET
Data refreshes hourly during market hours. Next update: 7:21 PM
Data refreshes hourly during market hours. Next update: 7:21 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTXR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 52 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 40 SELL |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$849 | 51 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$290 | 64 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 54 HOLD |
